Abstract | BACKGROUND: METHODS: Studies that evaluated RT versus no-RT after CR to RCHOP for DLBCL patients were searched in databases. Hazard ratios (HR) with their respective 95% confidence intervals (CI) were calculated using a random-effects model. RESULTS: A total of 4 qualified retrospective studies (633 patients) were included in this review. The results suggested that RT improved overall survival (OS; HR 0.33, 95% CI 0.14-0.77) and progression-free/event-free survival (PFS/EFS; HR 0.24, 95% CI 0.11-0.50) in all patients compared with no-RT. In a subgroup analysis of patients with stage III-IV DLBCL, RT improved PFS/EFS (HR 0.19, 95% CI 0.07-0.51) and local control (HR 0.12, 95% CI 0.03-0.44), with a trend of improving OS (HR 0.35, 95% CI 0.12-1.05). CONCLUSION: Consolidation RT could significantly improve outcomes of DLBCL patients who achieved a CR to RCHOP. However, the significance of these results was limited by these retrospective data. Further investigation of the role of consolidation RT in the rituximab era is needed.
|
Authors | Chunhong Hu, Chao Deng, Wen Zou, Guangsen Zhang, Jingjing Wang |
Journal | Acta haematologica
(Acta Haematol)
Vol. 134
Issue 2
Pg. 111-8
( 2015)
ISSN: 1421-9662 [Electronic] Switzerland |
PMID | 25925586
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2015 S. Karger AG, Basel. |
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents
- R-CHOP protocol
- Rituximab
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage, therapeutic use)
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Cyclophosphamide
(administration & dosage, therapeutic use)
- Doxorubicin
(administration & dosage, therapeutic use)
- Humans
- Induction Chemotherapy
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, radiotherapy)
- Prednisone
(administration & dosage, therapeutic use)
- Radiotherapy, Adjuvant
- Retrospective Studies
- Rituximab
- Survival Analysis
- Vincristine
(administration & dosage, therapeutic use)
|